Download PDF
Kardiologie up2date 2013; 09(01): 13-19
DOI: 10.1055/s-0032-1326364
Hotline – Aortenerkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Iatrogene Vorhofseptumdefekte – klinische Relevanz?

Tushar Chatterjee
,
Christoph A. Nienaber
Further Information

Publication History

Publication Date:
28 March 2013 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

Transseptal catheterization is used by cardiologists to gain access in the left atrium. Over the last two decades, there has been renewed interest in the use of the transeptal puncture approach during the treatment of structural or electrophysiologic heart disease. This article gives an overview of the frequency and relevance of iatrogenic atrial septal defects.

 

  • Literatur

  • 1 Liu TJ, Lai HC, Lee WL et al. Immediate and late outcomes of patients undergoing transseptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases. Am Heart J 2006; 151: 235-241
    CrossrefPubMedGoogle Scholar
  • 2 De Ponti R, Cappato R, Curnis A et al. Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years. J Am Coll Cardiol 2006; 47: 1037-1042
    CrossrefPubMedGoogle Scholar
  • 3 Harikrishnan S, Titus T, Tharakan JM. Septal defects after percutaneous mitral valvotomy – all are not innocent. Int J Cardiol 2005; 99: 329-330
    CrossrefPubMedGoogle Scholar
  • 4 Nakao M, Ch'ng JK, Sin YK et al. Acquired right-to-left shunt through an atrial septal perforation with cyanosis after percutaneous transvenous mitral commissurotomy. J Am Soc Echocardiogr 2005; 18: 183-184
    PubMedGoogle Scholar
  • 5 L'Epine Y, Drobinski G, Sotirov Y et al. Right heart failure due to an inter-atrial shunt after percutaneous mitral balloon dilatation. Eur Heart J 1989; 10: 285-287
    PubMedGoogle Scholar
  • 6 Zanchetta M, Onorato E, Rigatelli G et al. Use of Amplatzer septal occluder in a case of residual atrial septal defect causing bidirectional shunting after percutaneous Inoue mitral balloon valvuloplasty. J Invasive Cardiol 2001; 13: 223-226
    PubMedGoogle Scholar
  • 7 McCready JW, Moon JC, Chow AW. Right to left shunt following radiofrequency catheter ablation of atrial fibrillation in a patient with complex congenital heart disease. Europace 2010; 12: 289-290
    CrossrefPubMedGoogle Scholar
  • 8 Pitcher A, Schrale RG, Mitchell AR et al. Percutaneous closure of an iatrogenic atrial septal defect. Eur J Echocardiogr 2008; 9: 294-295
    PubMedGoogle Scholar
  • 9 Fraker Jr TD, Harris PJ, Behar VS et al. Detection and exclusion of interatrial shunts by two-dimensional echocardiography and peripheral venous injection. Circulation 1979; 59: 379-384
    CrossrefPubMedGoogle Scholar
  • 10 Hausmann D, Daniel WG, Mügge A et al. Value of transesophageal color Doppler echocardiography for detection of different types of atrial septal defect in adults. J Am Soc Echocardiogr 1992; 5: 481-488
    PubMedGoogle Scholar
  • 11 Hoey ET, Gopalan D, Ganesh V et al. Atrial septal defects. magnetic resonance and computed tomography appearances. J Med Imaging Radiat Oncol 2009; 53: 261-270
    CrossrefPubMedGoogle Scholar
  • 12 Inoue K, Owaki T, Nakamura T et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87: 394-402
    PubMedGoogle Scholar
  • 13 Vahanian A, Baumgartner H, Bax J et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines on the management of valvular heart disease. Eur Heart J 2007; 28: 230-268
    CrossrefPubMedGoogle Scholar
  • 14 Vahanian A, Cormier B, Iung B. Percutaneous transvenous mitral commissurotomy using the Inoue balloon. international experience. Cathet Cardiovasc Diagn 1994; 2: 8-15
    PubMedGoogle Scholar
  • 15 Bouleti C, Iung B, Laouénan C et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation 2012; 125: 2119-2127
    CrossrefPubMedGoogle Scholar
  • 16 McKay CR, Kawanishi DT, Rahimtoola SH. Catheter balloon valvuloplasty of the mitral valve in adults using a double-balloon technique. Early hemodynamic results. JAMA 1987; 257: 1753-1761
    CrossrefPubMedGoogle Scholar
  • 17 Casale P, Block PC, O'Shea JP et al. Atrial septal defect after percutaneous mitral balloon valvuloplasty: immediate results and follow-up. J Am Coll Cardiol 1990; 15: 1300-1304
    CrossrefPubMedGoogle Scholar
  • 18 Yoshida K, Yoshikawa J, Akasaka T et al. Assessment of left-to-right atrial shunting after percutaneous mitral valvuloplasty by transesophageal color Doppler flow-mapping. Circulation 1989; 80: 1521-1526
    CrossrefPubMedGoogle Scholar
  • 19 Cequier A, Bonan R, Dyrda I et al. Atrial shunting after percutaneous mitral valvuloplasty. Circulation 1990; 81: 1190
    CrossrefPubMedGoogle Scholar
  • 20 Daniel WG, Baumgartner H, Gohlke-Bärwolf C et al. Klappenvitien im Erwachsenenalter. Clin Res Cardiol 2006; 95: 620-641
    CrossrefPubMedGoogle Scholar
  • 21 Feldman T, Wasserman HS, Herrmann HC et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 2005; 46: 2134-2140
    CrossrefPubMedGoogle Scholar
  • 22 Feldman T, Kar S, Rinaldi M et al. EVEREST Investigators. ercutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009; 54: 686-694
    CrossrefPubMedGoogle Scholar
  • 23 Feldman T, Foster E, Glower DD et al. EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
    CrossrefPubMedGoogle Scholar
  • 24 Biner S, Siegel RJ, Feldman T et al. EVEREST investigators. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail 2012; 14: 939-945
    CrossrefPubMedGoogle Scholar
  • 25 Smith T, McGinty P, Bommer W et al. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv 2012; 80: 678-685
    CrossrefPubMedGoogle Scholar
  • 26 Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375
    CrossrefPubMedGoogle Scholar
  • 27 Chugh SS, Blackshear JL, Shen WK et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378
    CrossrefPubMedGoogle Scholar
  • 28 Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. Cardiol Clin 2008; 26: 267-275
    CrossrefPubMedGoogle Scholar
  • 29 Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764
    CrossrefPubMedGoogle Scholar
  • 30 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
    CrossrefPubMedGoogle Scholar
  • 31 Camm AJ, Kirchhof P, Lip GYH. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
    CrossrefPubMedGoogle Scholar
  • 32 ACTIVE WritingGroup of the ACTIVE Investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912
    CrossrefPubMedGoogle Scholar
  • 33 Connolly SJ, Pogue J, Hart RG. ACTIVE Investigators et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078
    CrossrefPubMedGoogle Scholar
  • 34 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419
    CrossrefPubMedGoogle Scholar
  • 35 Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 36 Wallentin L, Yusuf S, Ezekowitz MD et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983
    CrossrefPubMedGoogle Scholar
  • 37 Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000; 160: 41-46
    CrossrefPubMedGoogle Scholar
  • 38 Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759
    CrossrefPubMedGoogle Scholar
  • 39 Klein AL, Grimm RA, Murray RD et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420
    CrossrefPubMedGoogle Scholar
  • 40 Healey JS, Crystal E, Lamy A et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293
    CrossrefPubMedGoogle Scholar
  • 41 Bayard YL, Omran H, Neuzil P et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010; 6: 220-226
    CrossrefPubMedGoogle Scholar
  • 42 Viles-Gonzalez JF, Kar S, Douglas P et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012; 59: 923-929
    CrossrefPubMedGoogle Scholar
  • 43 Landmesser U, Holmes Jr DR. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2012; 33: 698-704
    CrossrefPubMedGoogle Scholar
  • 44 Omran H, Hardung D, Schmidt H et al. Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol 2003; 14: 56-59
    CrossrefPubMedGoogle Scholar
  • 45 Singh SM, Douglas PS, Reddy VY. The incidence and long-term clinical outcome of iatrogenic atrial septal defects secondary to transseptal catheterization with a 12F transseptal sheath. Circ Arrhythm Electrophysiol 2011; 4: 166-171
    CrossrefPubMedGoogle Scholar
  • 46 Rillig A, Meyerfeldt U, Birkemeyer R et al. Persistent iatrogenic atrial septal defect after pulmonary vein isolation: incidence and clinical implications. J Interv Card Electrophysiol 2008; 22: 177-181
    CrossrefPubMedGoogle Scholar
  • 47 Hammerstingl C, Lickfett L, Jeong KM et al. Persistence of iatrogenic atrial septal defect after pulmonary vein isolation – an underestimated risk?. Am Heart J 2006; 152: 362
    PubMedGoogle Scholar